Literature DB >> 9695715

Time course of enzyme induction in humans: effect of pentobarbital on nortriptyline metabolism.

C von Bahr1, E Steiner, Y Koike, J Gabrielsson.   

Abstract

To study the effect of induction we gave six male volunteers 10 mg nortriptyline three times a day for 4 weeks and 0.2 gm pentobarbital on days 8 to 21. Plasma and urinary levels of nortriptyline and metabolites were measured. The rate and extent of induction of the enzyme(s) were estimated by a model with use of nortriptyline concentrations. There was a marked decrease of nortriptyline levels after 2 days of pentobarbital treatment. Total clearance of nortriptyline increased more than twofold (range, 1.6-fold to 4.1-fold). Apparent metabolic clearance by 10-hydroxylation increased markedly. The decrease in nortriptyline levels was more rapid than the increase after pentobarbital cessation, fitting with the theory of the model. The induction of nortriptyline metabolism is probably mainly the result of an increase in a non-CYP 2D6 P450 isozyme, possibly CYP 3A4 or a CYP 2C form. More knowledge of induction characteristics of drugs should lead to better predictions of decreased effects and appearance of adverse effects. The kinetic model used for analysis of our data could then be useful.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9695715     DOI: 10.1016/S0009-9236(98)90018-2

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  21 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

3.  Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.

Authors:  T Kerbusch; A D Huitema; J Ouwerkerk; H J Keizer; R A Mathôt; J H Schellens; J H Beijnen
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

Review 4.  Pattern Recognition in Pharmacokinetic Data Analysis.

Authors:  Johan Gabrielsson; Bernd Meibohm; Daniel Weiner
Journal:  AAPS J       Date:  2015-09-03       Impact factor: 4.009

Review 5.  Role of variability in explaining ethanol pharmacokinetics: research and forensic applications.

Authors:  Ake Norberg; A Wayne Jones; Robert G Hahn; Johan L Gabrielsson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2018-09-12       Impact factor: 4.009

Review 7.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

8.  A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.

Authors:  A D Huitema; R A Mathôt; M M Tibben; S Rodenhuis; J H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

9.  Dealing with time-dependent pharmacokinetics during the early clinical development of a new leukotriene B4 synthesis inhibitor.

Authors:  Iñaki F Trocóniz; Ilonka Zsolt; María J Garrido; Marta Valle; Rosa M Antonijoan; Manel J Barbanoj
Journal:  Pharm Res       Date:  2006-06-21       Impact factor: 4.200

10.  Population pharmacokinetics of artesunate and dihydroartemisinin during long-term oral administration of artesunate to patients with metastatic breast cancer.

Authors:  Therese Ericsson; Antje Blank; Cornelia von Hagens; Michael Ashton; Angela Äbelö
Journal:  Eur J Clin Pharmacol       Date:  2014-09-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.